Printer Friendly

Sunshine Biopharma to negotiate with several Contract Research Organisations.

M2 PHARMA-September 5, 2014-Sunshine Biopharma to negotiate with several Contract Research Organisations

(C)2014 M2 COMMUNICATIONS

Sunshine Biopharma, a pharmaceutical company focused on the research, development and commercialisation of drugs for the treatment of various forms of cancer, is presently negotiating with several Contract Research Organisations, it was reported yesterday.

The company is negotiating with the intention of engaging one of them to initiate, compile and manage a regulatory master drug file for Adva-27a, the company's flagship anticancer compound. A master drug file includes all of the information that regulatory agencies require as part of the drug development and approval process.

Dr. Steve N. Slilaty, CEO of Sunshine Biopharma, said, 'Engaging a CRO is the next step in our Adva-27a drug development programme. We are delighted to have arrived at this advanced stage in the development of our Adva-27a. The CRO will compile the testing results conducted to date, follow and document the GMP manufacturing process, manage the large animal studies and file with the appropriate regulatory agencies for go-ahead with Phase I human trials.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 5, 2014
Words:186
Previous Article:DelMar Pharmaceuticals receives notice of allowance for US patent for VAL-083.
Next Article:Pharmaceutical Product Development acquires RCT Logic's exclusive license from Massachusetts General Hospital.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters